vs
Side-by-side financial comparison of Bio-Techne (TECH) and WORKIVA INC (WK). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($295.9M vs $238.9M, roughly 1.2× WORKIVA INC). Bio-Techne runs the higher net margin — 12.8% vs 4.9%, a 7.9% gap on every dollar of revenue. On growth, WORKIVA INC posted the faster year-over-year revenue change (19.5% vs -6.4%). Over the past eight quarters, WORKIVA INC's revenue compounded faster (16.6% CAGR vs 4.2%).
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
Workiva, Inc. is a global software-as-a-service (SaaS) company. It provides a cloud-based connected and reporting compliance platform that enables the use of connected data and automation of reporting across finance, accounting, risk, and compliance.
TECH vs WK — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $295.9M | $238.9M |
| Net Profit | $38.0M | $11.8M |
| Gross Margin | 64.6% | 80.7% |
| Operating Margin | 18.4% | 3.3% |
| Net Margin | 12.8% | 4.9% |
| Revenue YoY | -6.4% | 19.5% |
| Net Profit YoY | 68.3% | 234.0% |
| EPS (diluted) | $0.24 | $0.21 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $295.9M | $238.9M | ||
| Q3 25 | — | $224.2M | ||
| Q2 25 | $317.0M | $215.2M | ||
| Q1 25 | $316.2M | $206.3M | ||
| Q4 24 | $297.0M | $199.9M | ||
| Q3 24 | $289.5M | $185.6M | ||
| Q2 24 | $306.1M | $177.5M | ||
| Q1 24 | $303.4M | $175.7M |
| Q4 25 | $38.0M | $11.8M | ||
| Q3 25 | — | $2.8M | ||
| Q2 25 | $-17.7M | $-19.4M | ||
| Q1 25 | $22.6M | $-21.4M | ||
| Q4 24 | $34.9M | $-8.8M | ||
| Q3 24 | $33.6M | $-17.0M | ||
| Q2 24 | $40.6M | $-17.5M | ||
| Q1 24 | $49.1M | $-11.7M |
| Q4 25 | 64.6% | 80.7% | ||
| Q3 25 | — | 79.3% | ||
| Q2 25 | 62.7% | 77.0% | ||
| Q1 25 | 67.9% | 76.6% | ||
| Q4 24 | 65.3% | 77.1% | ||
| Q3 24 | 63.2% | 76.5% | ||
| Q2 24 | 66.4% | 76.8% | ||
| Q1 24 | 67.4% | 76.4% |
| Q4 25 | 18.4% | 3.3% | ||
| Q3 25 | — | -1.5% | ||
| Q2 25 | -7.5% | -10.3% | ||
| Q1 25 | 12.2% | -12.0% | ||
| Q4 24 | 16.0% | -6.7% | ||
| Q3 24 | 13.8% | -11.7% | ||
| Q2 24 | 15.0% | -13.0% | ||
| Q1 24 | 22.1% | -10.4% |
| Q4 25 | 12.8% | 4.9% | ||
| Q3 25 | — | 1.2% | ||
| Q2 25 | -5.6% | -9.0% | ||
| Q1 25 | 7.1% | -10.4% | ||
| Q4 24 | 11.7% | -4.4% | ||
| Q3 24 | 11.6% | -9.2% | ||
| Q2 24 | 13.3% | -9.9% | ||
| Q1 24 | 16.2% | -6.7% |
| Q4 25 | $0.24 | $0.21 | ||
| Q3 25 | — | $0.05 | ||
| Q2 25 | $-0.11 | $-0.35 | ||
| Q1 25 | $0.14 | $-0.38 | ||
| Q4 24 | $0.22 | $-0.15 | ||
| Q3 24 | $0.21 | $-0.31 | ||
| Q2 24 | $0.26 | $-0.32 | ||
| Q1 24 | $0.31 | $-0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $172.9M | $338.8M |
| Total DebtLower is stronger | $260.0M | — |
| Stockholders' EquityBook value | $2.0B | $-5.4M |
| Total Assets | $2.5B | $1.5B |
| Debt / EquityLower = less leverage | 0.13× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $172.9M | $338.8M | ||
| Q3 25 | — | $315.9M | ||
| Q2 25 | $162.2M | $284.3M | ||
| Q1 25 | $140.7M | $242.0M | ||
| Q4 24 | $177.5M | $301.8M | ||
| Q3 24 | $187.5M | $248.2M | ||
| Q2 24 | $152.9M | $267.9M | ||
| Q1 24 | $145.3M | $296.1M |
| Q4 25 | $260.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $346.0M | — | ||
| Q1 25 | $330.0M | — | ||
| Q4 24 | $300.0M | — | ||
| Q3 24 | $300.0M | — | ||
| Q2 24 | $319.0M | — | ||
| Q1 24 | $389.0M | — |
| Q4 25 | $2.0B | $-5.4M | ||
| Q3 25 | — | $-36.9M | ||
| Q2 25 | $1.9B | $-66.5M | ||
| Q1 25 | $2.0B | $-75.7M | ||
| Q4 24 | $2.1B | $-41.7M | ||
| Q3 24 | $2.1B | $-50.8M | ||
| Q2 24 | $2.1B | $-77.7M | ||
| Q1 24 | $2.0B | $-83.2M |
| Q4 25 | $2.5B | $1.5B | ||
| Q3 25 | — | $1.4B | ||
| Q2 25 | $2.6B | $1.3B | ||
| Q1 25 | $2.6B | $1.3B | ||
| Q4 24 | $2.7B | $1.4B | ||
| Q3 24 | $2.7B | $1.3B | ||
| Q2 24 | $2.7B | $1.2B | ||
| Q1 24 | $2.7B | $1.2B |
| Q4 25 | 0.13× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.18× | — | ||
| Q1 25 | 0.16× | — | ||
| Q4 24 | 0.14× | — | ||
| Q3 24 | 0.14× | — | ||
| Q2 24 | 0.15× | — | ||
| Q1 24 | 0.19× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $51.0M |
| Free Cash FlowOCF − Capex | — | $50.7M |
| FCF MarginFCF / Revenue | — | 21.2% |
| Capex IntensityCapex / Revenue | — | 0.1% |
| Cash ConversionOCF / Net Profit | — | 4.31× |
| TTM Free Cash FlowTrailing 4 quarters | — | $138.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $51.0M | ||
| Q3 25 | — | $46.2M | ||
| Q2 25 | $98.2M | $50.3M | ||
| Q1 25 | $41.1M | $-7.4M | ||
| Q4 24 | $84.3M | $44.0M | ||
| Q3 24 | $63.9M | $18.9M | ||
| Q2 24 | $75.5M | $-14.0K | ||
| Q1 24 | $81.0M | $24.8M |
| Q4 25 | — | $50.7M | ||
| Q3 25 | — | $46.1M | ||
| Q2 25 | $93.3M | $49.3M | ||
| Q1 25 | $31.0M | $-8.1M | ||
| Q4 24 | $77.5M | $43.2M | ||
| Q3 24 | $54.7M | $18.7M | ||
| Q2 24 | $57.5M | $-122.0K | ||
| Q1 24 | $64.5M | $24.6M |
| Q4 25 | — | 21.2% | ||
| Q3 25 | — | 20.5% | ||
| Q2 25 | 29.4% | 22.9% | ||
| Q1 25 | 9.8% | -3.9% | ||
| Q4 24 | 26.1% | 21.6% | ||
| Q3 24 | 18.9% | 10.1% | ||
| Q2 24 | 18.8% | -0.1% | ||
| Q1 24 | 21.3% | 14.0% |
| Q4 25 | — | 0.1% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | 1.5% | 0.5% | ||
| Q1 25 | 3.2% | 0.4% | ||
| Q4 24 | 2.3% | 0.4% | ||
| Q3 24 | 3.2% | 0.1% | ||
| Q2 24 | 5.9% | 0.1% | ||
| Q1 24 | 5.4% | 0.1% |
| Q4 25 | — | 4.31× | ||
| Q3 25 | — | 16.57× | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.82× | — | ||
| Q4 24 | 2.42× | — | ||
| Q3 24 | 1.90× | — | ||
| Q2 24 | 1.86× | — | ||
| Q1 24 | 1.65× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
WK
| License And Service | $219.3M | 92% |
| XBRL Professional Services | $16.4M | 7% |
| Other Services | $3.2M | 1% |
